Ethyl pak-modified diketone biscarboline and piperazine, its preparation, activity and application

A technology of diketone and ethyl, applied in medical preparations containing active ingredients, chemical instruments and methods, extracellular fluid diseases, etc., can solve problems such as no curative effect, pleural cavity and abdominal cavity bleeding

Active Publication Date: 2022-04-22
CAPITAL UNIVERSITY OF MEDICAL SCIENCES
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there are two insurmountable problems in the treatment of ischemic stroke with rtPA
The first complication is that rtPA is not effective in patients with ischemic stroke >4 hours
The second problem is that continuous use of rtPA can cause cerebral, thoracic and abdominal hemorrhage

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ethyl pak-modified diketone biscarboline and piperazine, its preparation, activity and application
  • Ethyl pak-modified diketone biscarboline and piperazine, its preparation, activity and application
  • Ethyl pak-modified diketone biscarboline and piperazine, its preparation, activity and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Preparation of (3S)-1-(2,2-dimethoxyeth-1-yl)-2,3,4,9-tetrahydro-β-carboline-3-carboxylic acid benzyl ester (1)

[0021] Add 5 mL of 1,1,3,3-tetramethoxypropane and 3.5 mL of trifluoroacetic acid to 150 mL of dichloromethane under stirring at 0°C, react for 40 minutes, then add 5 g (17.00 mmol) of Trp-OBzl, The reaction was carried out at 40°C. After reacting for 4 hours, the pH value of the reaction solution was adjusted to 7 with concentrated ammonia water at 0°C with stirring, concentrated under reduced pressure, and the residue was dissolved in 100 mL of dichloromethane, washed three times with saturated aqueous sodium bicarbonate solution, saturated chlorinated The sodium solution was washed 3 times, the dichloromethane phase was dried with anhydrous sodium sulfate for 12 hours, filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain a yellow oil, which was purified by silica gel column chromatography to obtain 5.50 g (82%)...

Embodiment 2

[0022] Example 2 Preparation of (3S)-1-(2,2-dimethoxyeth-1-yl)-2,3,4,9-tetrahydro-β-carboline-3-carboxylic acid (2)

[0023] 5.50g (13.96mmol) (3S)-1-(2,2-dimethoxyeth-1-yl)-2,3,4,9-tetrahydro-β-carboline-3-carboxylic acid benzyl The ester (1) was dissolved in 50 mL of acetone, and NaOH aqueous solution (2M) was added thereto under stirring at 0° C. to adjust the pH value of the solution to 12, and reacted for 3 hours to keep the pH value of the reaction solution at 12. Thereafter, the pH was adjusted to neutral with saturated potassium hydrogensulfate aqueous solution, and concentrated under reduced pressure. 50 mL of acetone was added to the residue, the insoluble solid was removed by filtration, and the filtrate was concentrated to dryness under reduced pressure to obtain 3.63 g (86%) of the title compound as a yellow sticky substance. ESI-MS(m / e):303[M-H] - .

Embodiment 3

[0024] Example 3 Preparation of (2'S,5'S)-tetrahydropyrazine[1',2':1,6]bis[1S,1R-(1-dimethoxyeth-1-yl)-2,3,4 ,9-Tetrahydro-1H-pyridino[3,4-b]indole]-1',4'-dione (3)

[0025] 3.63g (11.94mmol) (3S)-1-(2,2-dimethoxyeth-1-yl)-2,3,4,9-tetrahydro-β-carboline-3-carboxylic acid (2 ) was dissolved in 20 mL of anhydrous N,N-dimethylformamide, and then 5.44 g (14.32 mmol) of 2-(7-azobenzotriazole)-N,N,N',N'-tetra Methylurea hexafluorophosphate, the solution was adjusted to pH 8 with N-methylmorpholine under stirring at 0°C, and after stirring at room temperature for 16 hours, 150 mL of distilled water was added to the reaction solution, followed by extraction with dichloromethane ( 50mL×3), combined the dichloromethane phase, and then washed with saturated aqueous sodium chloride solution (50mL×3), the dichloromethane phase was dried with anhydrous sodium sulfate for 12 hours, filtered, and the filtrate was concentrated to dryness under reduced pressure to obtain a yellow The oil was ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses (2'S,5'S)-tetrahydropyrazine[1',2':1,6]bis[1S,1R-(1-ethyl-Pro-Ala-Lys)-2, 3,4,9-tetrahydro-1H-pyridin[3,4-b]indole]-1',4'-dione discloses its preparation method, discloses its thrombolytic activity, discloses Its antithrombotic activity also discloses that it remains effective for 24 hours after the onset of ischemic stroke. Therefore, the present invention discloses its application in the preparation of thrombolytic drugs, its application in the preparation of antithrombotic drugs, its application in the preparation of drugs that are still effective for ischemic stroke for 24 hours, and its application in the preparation of antithrombotic drugs. Its application in the preparation of a drug with triple effects of thrombolysis, antithrombosis and ischemic stroke still effective for 24 hours.

Description

technical field [0001] The present invention relates to (2'S,5'S)-tetrahydropyrazine[1',2':1,6]bis[1S,1R-(1-ethyl-Pro-Ala-Lys)-2,3,4, 9-tetrahydro-1H-pyridine[3,4-b]indole]-1',4'-dione, related to its preparation method, related to its thrombolytic activity, related to its antithrombotic activity and related to It remains effective for 24 hours after the onset of ischemic stroke. Therefore the present invention relates to its application in the preparation of thrombolytic drugs, to its application in the preparation of antithrombotic drugs, to its application in the preparation of drugs that are still effective for 24 hours after the onset of ischemic stroke, and to its use in the preparation of drugs with lytic properties. Thrombotic, antithrombotic, and triple-action drugs that are effective for 24 hours after the onset of ischemic stroke. The invention belongs to the field of biomedicine. [0002] technical background [0003] Ischemic stroke is a common and serious cer...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07K5/097A61K38/06A61P7/02A61P9/10
CPCC07K5/0823C07K19/00A61P7/02A61P9/10A61K38/00
Inventor 赵明彭师奇冯琦琦张娟凤
Owner CAPITAL UNIVERSITY OF MEDICAL SCIENCES
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap